Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

I had abandoned my transverse abdominis (TA or TVA). Unlike the rectus abdominis (those six-pack abs we typically think of in the core), the TA muscles support the spine and the way we hold our ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

Real Avid has announced a new tool for keeping inline muzzleloader ignitions functioning reliably. The Breech Plug 4-in-1 Scraper combines several key tools into one easy-to-carry, hard-to-lose unit.

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed for now on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug ...